دورية أكاديمية

Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?

التفاصيل البيبلوغرافية
العنوان: Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
المؤلفون: Ribeiro JT; Division of Medical Oncology, University of Lisboa Medical School, Centro Hospitalar Lisboa Norte, Lisboa, Portugal., Macedo LT; Division of Medical Oncology, Hospital de Clinicas, State University Medical School of Campinas, Campinas, Brazil., Curigliano G; Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy. Electronic address: giuseppe.curigliano@ieo.it., Fumagalli L; Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy., Locatelli M; Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy., Dalton M; Oxford University Medical School, Brasenose College, University of Oxford, Oxford, UK., Quintela A; Division of Medical Oncology, University of Lisboa Medical School, Centro Hospitalar Lisboa Norte, Lisboa, Portugal., Carvalheira JBC; Division of Medical Oncology, Hospital de Clinicas, State University Medical School of Campinas, Campinas, Brazil., Manunta S; Sassari University Medical School, Ospedale S. Campus, Sassari, Italy., Mazzarella L; Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy., Brollo J; Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy., Goldhirsch A; Division of Medical Oncology, Department of Medicine, European Institute of Oncology, Milan, Italy.
المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2012 Mar; Vol. 23 (3), pp. 547-555. Date of Electronic Publication: 2011 Sep 06.
نوع المنشور: Journal Article; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : London : Elsevier
Original Publication: Dordrecht ; Boston : Kluwer Academic Publishers, c1990-
مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*drug therapy , Cytotoxins/*therapeutic use, Clinical Trials as Topic ; Female ; Humans
مستخلص: Background: Despite current trend of targeted therapy development, cytotoxic agents are a mainstay of treatment of patients with breast cancer. We reviewed recent advances in cytotoxic therapy for patients with metastatic breast cancer (MBC).
Materials and Methods: Medline searches were conducted for English language studies using the term 'MBC' and 'cytotoxic drugs'. The data search was restricted to the period 2000-2011.
Results: Several novel cytotoxic compounds, all microtubule inhibitors, have been approved for clinical use in MBC: (i) nab-paclitaxel, reported to improve tumour response and decrease hypersensitivity reactions in comparison with other taxanes; (ii) ixabepilone, shown to have clinical benefit in taxane- and anthracycline-resistant disease and (iii) eribulin, shown to improve overall survival in heavily pre-treated patients, when compared with best available standard treatment. Agents, such as larotaxel, vinflunine, trabectidin and formulations, including cationic liposomal paclitaxel or paclitaxel poliglumex, are currently under evaluation in phase II/III trials.
Conclusion: Toxicity and chemotherapy resistance are still major limitations in the treatment of patients with MBC. Further research into new cytotoxic compounds is needed in order to maximise benefit, whilst minimising toxicity.
المشرفين على المادة: 0 (Antineoplastic Agents)
0 (Cytotoxins)
تواريخ الأحداث: Date Created: 20110908 Date Completed: 20120612 Latest Revision: 20240229
رمز التحديث: 20240229
DOI: 10.1093/annonc/mdr382
PMID: 21896541
قاعدة البيانات: MEDLINE
الوصف
تدمد:1569-8041
DOI:10.1093/annonc/mdr382